Aridis is a late‑stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life‑threatening infections. mAbs represent an innovative treatment approach that harnesses the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. The majority of Aridis’ product candidates are derived by employing a differentiated antibody discovery platform called MabIgX. The proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life‑threatening bacterial infections, primarily hospital‑acquired pneumonia, or HAP, and ventilator‑associated pneumonia, or VAP. Three of these product candidates have exhibited promising preclinical data and clinical data are available from two completed studies and are in pivotal trial stage. The Company’s lead product candidate, AR‑301 targets the alpha toxin produced by gram‑positive bacteria Staphylococcus aureus, or S. aureus, a common pathogen associated with HAP and VAP. Aridis conducted an end‑of‑Phase 2 meeting with the U.S. Food and Drug Administration, or FDA, and expect to initiate a Phase 3 pivotal trial for AR‑301 in the second half of 2018.

Recent News
Dec 12, 2018

Aridis Pharmaceuticals (NASDAQ: ARDS) announced today that the first subject has been enrolled in a Phase 1/2a clinical study evaluating the investigational candidate AR-501 for treatment of...

Dec 4, 2018

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that the Cystic Fibrosis Foundation (CF Foundation) has more than doubled its research agreement for the clinical development of AR-501 from

Nov 13, 2018

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies, or mAbs, to...

Stock Info